Cabaletta Bio, Inc.

Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The company utilizes its proprietary CABA® platform to advance engineered T cell therapies, aiming to provide deep, durable, and potentially curative responses with one-time administration, potentially eliminating the need for chronic immunosuppression. The company's lead candidate, rese-cel (resecabtagene autoleucel), is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. It is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program across multiple autoimmune indications, including systemic lupus erythematosus (SLE), myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.